The cost‐effectiveness of consistent and early intervention of harm reduction for injecting drug users in Bangladesh
- 11 January 2010
- Vol. 105 (2), 319-328
- https://doi.org/10.1111/j.1360-0443.2009.02755.x
Abstract
To assess the cost-effectiveness of the CARE-SHAKTI harm reduction intervention for injecting drug users (IDUs) over a 3-year period, the impact on the cost-effectiveness of stopping after 3 years and how the cost-effectiveness might vary with baseline human immunodeficiency virus (HIV) prevalence. Economic cost data were collected from the study site and combined with impact estimates derived from a dynamic mathematical model. Dhaka, Bangladesh, where the HIV prevalence has remained low despite high-risk sexual and injecting behaviours, and growing HIV epidemics in neighbouring countries. The cost per HIV infection prevented over the first 3 years was USD 110.4 (33.1-182.3). The incremental cost-effectiveness of continuing the intervention for a further year, relative to stopping at the end of year 3, is USD 97 if behaviour returns to pre-intervention patterns. When baseline IDU HIV prevalence is increased to 40%, the number of HIV infections averted is halved for the 3-year period and the cost per HIV infection prevented doubles to USD 228. The analysis confirms that harm reduction activities are cost-effective. Early intervention is more cost-effective than delaying activities, although this should not preclude later intervention. Starting harm reduction activities when IDU HIV prevalence reaches as high as 40% is still cost-effective. Continuing harm reduction activities once a project has matured is vital to sustaining its impact and cost-effectiveness.This publication has 23 references indexed in Scilit:
- Modelling the impact and cost-effectiveness of the HIV intervention programme amongst commercial sex workers in Ahmedabad, Gujarat, IndiaBMC Public Health, 2007
- HIV prevention costs and program scale: data from the PANCEA project in five low and middle-income countriesBMC Health Services Research, 2007
- Could the CARE–SHAKTI intervention for injecting drug users be maintaining the low HIV prevalence in Dhaka, Bangladesh?Addiction, 2006
- The Cost-Effectiveness of Expanding Harm Reduction Activities for Injecting Drug Users in Odessa, UkraineSexually Transmitted Diseases, 2006
- The Costs of Treating Curable Sexually Transmitted Infections in Low- and Middle-Income Countries: A Systematic ReviewSexually Transmitted Diseases, 2006
- From Trial Intervention to Scale-Up: Costs of an Adolescent Sexual Health Program in Mwanza, TanzaniaSexually Transmitted Diseases, 2006
- The cost‐effectiveness of HIV preventive measures among injecting drug users in Svetlogorsk, BelarusAddiction, 2004
- Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysisHealth Policy and Planning, 2001
- HIV/AIDS Prevention and Care Interventions in Sub‐Saharan Africa: An Econometric Analysis of the Costs of Scaling‐UpSouth African Journal of Economics, 2000
- Research article. The impact of a needle exchange's closurePublic Health Reports, 1999